文献速递消化系统肿瘤

整合深度学习与病理分期标志物的结直肠癌辅助化疗临床决策支持系统:开发与验证研究

A clinical decision support system optimising adjuvant chemotherapy for colorectal cancers by integrating deep learning and pathological staging markers: a development and validation study.
PubMed 文献 · Lancet Oncol · 2022-08-11

基于DoMore-v1-CRC标志物与病理分期构建结直肠癌辅助治疗决策支持系统,在挪威和英国两个社区队列997例Ⅱ-Ⅲ期R0患者中开发,并在QUASAR 2试验1075例接受单药卡培他滨治疗的患者中外部验证。新系统对高危vs低危的HR为10.71(95%CI 6.39-17.93;p<0.0001),中危vs低危的HR为3.06(95%CI 1.73-5.42;p=0.0001),3年癌症特异性生存低危组97.2%、中危组94.8%、高危组77.6%;基于指南的分组预后区分能力较差,低危组仅142例(13%)。

要点

  • 新风险分层系统在验证队列中高危vs低危的HR为10.71(95%CI 6.39-17.93;p<0.0001)。
  • 中危vs低危的HR为3.06(95%CI 1.73-5.42;p=0.0001)。
  • 3年癌症特异性生存:低危组97.2%、中危组94.8%、高危组77.6%。

核心结论

  • 整合DoMore-v1-CRC与病理分期标志物提供的临床决策支持系统,比其组成元素更准确地进行风险分层,并识别出比当前指南低危组更多具有相似良好预后的Ⅱ期和Ⅲ期结直肠癌患者。
  • 作者认为,在这些患者中避免辅助化疗可能是安全的,并可能降低发病率、死亡率和治疗费用。

研究设计与样本

  • 开发队列为来自挪威和英国两个社区队列的997例Ⅱ期或Ⅲ期、无残留肿瘤(R0)的结直肠癌患者。
  • 外部验证队列为QUASAR 2试验中1075例Ⅱ期或Ⅲ期R0结直肠癌患者,接受单药卡培他滨治疗。
  • 使用Cox回归分析评估风险分层系统,主要结局为癌症特异性生存。

主要发现

  • 验证队列主要分析中,高危vs低危的HR为10.71(95%CI 6.39-17.93;p<0.0001),中危vs低危的HR为3.06(95%CI 1.73-5.42;p=0.0001)。
  • 估计3年癌症特异性生存:低危组97.2%(95%CI 95.1-98.4;n=445[41%]),中危组94.8%(95%CI 91.7-96.7;n=339[32%]),高危组77.6%(95%CI 72.1-82.1;n=291[27%])。
  • 基于指南的风险分组预后区分能力和信息量较差,低危组仅包含1075例患者中的142例(13%)。

关键数值与推荐

  • 风险分层系统基于病理肿瘤分期(pT<4或pT4)、病理淋巴结分期(pN0、pN1或pN2)、非pN2时淋巴结采样数(≤12或>12)以及DoMore-v1-CRC分类(预后良好、不确定或不良)构建。

临床怎么用

  • 作者认为,在该系统识别为低危的Ⅱ期和Ⅲ期结直肠癌患者中避免辅助化疗可能是安全的,并可能降低发病率、死亡率和治疗费用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The DoMore-v1-CRC marker was recently developed using deep learning and conventional haematoxylin and eosin-stained tissue sections, and was observed to outperform established molecular and morphological markers of patient outcome after primary colorectal cancer resection. The aim of the present study was to develop a clinical decision support system based on DoMore-v1-CRC and pathological staging markers to facilitate individualised selection of adjuvant treatment. METHODS: We estimated cancer-specific survival in subgroups formed by pathological tumour stage (pT<4 or pT4), pathological nodal stage (pN0, pN1, or pN2), number of lymph nodes sampled (≤12 or >12) if not pN2, and DoMore-v1-CRC classification (good, uncertain, or poor prognosis) in 997 patients with stage II or III colorectal cancer considered to have no residual tumour (R0) from two community-based cohorts in Norway and the UK, and used these data to define three risk groups. An external cohort of 1075 patients with stage II or III R0 colorectal cancer from the QUASAR 2 trial was used for validation; these patients were treated with single-agent capecitabine. The proposed risk stratification system was evaluated using Cox regression analysis. We similarly evaluated a risk stratification system intended to reflect current guidelines and clinical practice. The primary outcome was cancer-specific survival. FINDINGS: The new risk stratification system provided a hazard ratio of 10·71 (95% CI 6·39-17·93; p<0·0001) for high-risk versus low-risk patients and 3·06 (1·73-5·42; p=0·0001) for intermediate versus low risk in the primary analysis of the validation cohort. Estimated 3-year cancer-specific survival was 97·2% (95% CI 95·1-98·4; n=445 [41%]) for the low-risk group, 94·8% (91·7-96·7; n=339 [32%]) for the intermediate-risk group, and 77·6% (72·1-82·1; n=291 [27%]) for the high-risk group. The guideline-based risk grouping was observed to be less prognostic and informative (the low-risk group comprised only 142 [13%] of the 1075 patients). INTERPRETATION: Integrating DoMore-v1-CRC and pathological staging markers provided a clinical decision support system that risk stratifies more accurately than its constituent elements, and identifies substantially more patients with stage II and III colorectal cancer with similarly good prognosis as the low-risk group in current guidelines. Avoiding adjuvant chemotherapy in these patients might be safe, and could reduce morbidity, mortality, and treatment costs. FUNDING: The Research Council of Norway.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Kleppe A, Skrede OJ, De Raedt S, et al. A clinical decision support system optimising adjuvant chemotherapy for colorectal cancers by integrating deep learning and pathological staging markers: a development and validation study. Lancet Oncol. 2022. PMID: 35964620. doi:10.1016/S1470-2045(22)00391-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。